Adipotide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Adipotide

Also known as: CKGGRAKDC-GG-(D)(KLAKLAK)2, Proapoptotic peptidomimetic targeting white adipose tissue, ATS-KLAKLAK, Fat-targeted peptidomimetic

Ligand-directed peptidomimetic / pro-apoptotic peptide conjugate

Research chemicalLast updated: October 19, 2026Based on 9 peer-reviewed studiesPreclinical data only — no human trials

What it is

Adipotide is a compound studied in animals for reducing body fat by cutting off the blood supply to fat tissue, causing it to break down. Early research showed significant weight loss in obese monkeys, but it also caused kidney toxicity. No FDA-approved use; research remains at a preclinical stage.

The scientific side

Adipotide is a peptidomimetic composed of a white adipose tissue (WAT) vascular-targeting sequence (CKGGRAKDC) linked to a pro-apoptotic peptide domain [(D)(KLAKLAK)2]. It is designed to home to prohibitin (PHB1)-expressing endothelial cells on the vasculature of white adipose tissue and induce targeted apoptosis within those blood vessels, leading to reduction of WAT and weight loss. In obese non-human primates, treatment resulted in rapid weight loss, reduced white adipose tissue mass confirmed by MRI and DEXA, and improved insulin resistance. In obese mice, a pro-apoptotic peptide with the same mechanism improved glucose tolerance rapidly and in a weight- and food intake-independent manner, and altered lipid metabolism and mitochondrial pathways in adipose tissue. A nanoparticle-targeted formulation using the same PHB-targeting approach (KLA-PTNP) similarly reduced body weight and improved adipose tissue function in diet-induced obese mice. The adipose targeting sequence (ATS) has also been studied as a targeting vehicle for liposomal drug delivery to adipose endothelium. PHB1 on the adipose vascular endothelium also mediates bidirectional long-chain fatty acid transport, and ANX2/PHB interaction regulates fatty acid transport in WAT, providing additional biological context for PHB as an adipose vascular target.

Class: Ligand-directed peptidomimetic / pro-apoptotic peptide conjugate

Administration & storage

Administration
Systemic injection (PMID: 23871959)Route not specified in other abstracts (PMID: 22072637PMID: 22733798)
Storage
No storage conditions are described in the reviewed abstracts.
Cautions
Predictable and reversible changes in renal proximal tubule function were observed in monkeys from three species at experimentally determined optimal doses.,Dose-limiting renal toxicity (nephrotoxicity with proteinuria, casts, and increased serum creatinine) has been observed with a related peptidomimetic (BMTP-11) from the same D(KLAKLAK)2-containing class of agents in a human first-in-man trial.,ATS-targeted liposomes showed increased kidney uptake in biodistribution studies in ob/ob mice, raising potential off-target renal concerns.,One published comment suggests that the weight loss observed in obese monkeys may partly reflect a direct effect on food consumption rather than solely WAT apoptosis.,No human clinical trial data for Adipotide itself are available in the reviewed literature; all dosing and safety data are from animal studies only.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification